Lite Strategy, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Lite Strategy, Inc. (LITS) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$10.47 million for the 9-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-05-13
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-09-30 was -$7.90M, a 343.24% decline year-over-year.
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-09-30 was $3.25M.
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-09-30 was -$13.53M.
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-09-30 was -$1.09M, a 115.36% decline year-over-year.
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $14.31M.
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$13.20M, a 1232.16% decline from fiscal 2023.
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $1.17M, a 83.80% decline from fiscal 2022.
- Lite Strategy, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $7.20M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$10.47M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | -$9.25M 10-Q · filed 2026-02-17 | |||
| 2025-09-30 | -$7.90M 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $14.31M 10-K · filed 2025-09-26 | |||
| 2025-03-31 | $16.77M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $20.03M 10-Q · filed 2026-02-17 | |||
| 2024-09-30 | $3.25M 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | -$13.20M 10-K · filed 2025-09-26 | |||
| 2024-03-31 | -$14.54M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$11.73M 10-Q · filed 2025-02-12 | |||
| 2023-09-30 | -$13.53M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $1.17M 10-K · filed 2024-09-19 | |||
| 2023-03-31 | -$6.93M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$4.82M 10-Q · filed 2024-02-13 | |||
| 2022-09-30 | -$1.09M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $7.20M 10-K · filed 2023-09-26 | |||
| 2022-03-31 | $2.57M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $4.01M 10-Q · filed 2023-02-09 | |||
| 2021-09-30 | $7.08M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$3.79M 10-K · filed 2022-09-08 | |||
| 2021-03-31 | -$2.59M 10-Q · filed 2022-05-23 | |||
| 2020-12-31 | -$2.45M 10-Q/A · filed 2022-05-23 | |||
| 2020-09-30 | -$1.38M 10-Q/A · filed 2022-05-23 | |||
| 2020-06-30 | $2.74M 10-K · filed 2022-09-08 | |||
| 2020-03-31 | -$2.15M 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | -$952.00K 10-Q · filed 2021-02-04 | |||
| 2019-09-30 | -$3.61M 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | -$3.72M 10-K/A · filed 2022-05-23 | |||
| 2019-03-31 | -$5.88M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$4.56M 10-Q · filed 2020-02-06 | |||
| 2018-09-30 | -$7.19M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $4.85M 10-K · filed 2020-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |